Gilead Sciences acquired Immunomedics, Inc. for ~$21 billion, a transaction announced in October 2020.
Acquired the maker of Trodelvy, a first-in-class Trop-2 antibody-drug conjugate approved for triple-negative breast cancer, for $88.00 per share in cash, transforming Gilead's oncology portfolio with a commercial-stage product.
Acquired the maker of Trodelvy, a first-in-class Trop-2 antibody-drug conjugate approved for triple-negative breast cancer, for $88.00 per share in cash, transforming Gilead's oncology portfolio with a commercial-stage product.
Advisory firms were not disclosed for this transaction.